Company Overview and News

 
Pharma weekly wrap: FDC ban and Shivinder Singh#39;s U-turn hog the limelight

2018-09-16 moneycontrol
This was an action-packed week for the pharmaceutical and healthcare sectors with the ban on fixed drug combinations (FDCs), fresh developments in the Singh brothers' saga and Sun Pharmaceutical Industries' US Food and Drug Administration approval.
524715 5225 FORTIS 532915 SUNPHARMA RELIGARE Q0F IHHHF 532843

 
Need for arbitration to resolve differences, says Fortis promoter

2018-09-15 freepressjournal.in
New Delhi : The NCLT allowed former Fortis Healthcare promoter Shivinder Mohan Singh to withdraw his petition against elder brother Malvinder Mohan Singh and ex-Religare chief Sunil Godhwani.
FORTIS 532843

 
Shivinder: Decision to disassociate from brother still stands

2018-09-14 livemint
New Delhi: Former Ranbaxy Laboratories Ltd promoter and Fortis Healthcare Ltd co-founder Shivinder Singh said on Friday that he intends to use the “mediation process” to amicably resolve differences with his brother Malvinder Singh but that his decision to “disassociate” from his brother stands.
FORTIS 532915 RELIGARE 532843

 
An evening walk down Dalal Street | Photo finish on D-Street! Sensex ends over 350 points higher, Nifty races past 11,500

2018-09-14 moneycontrol
It’s a perfect photo finish for D-Street! The Nifty raced past 11,500 and ended the session above that mark. This is contrary to the negative moves that the market had in the first couple of days of the week.
SPARC 524715 BHRQY 532843 533278 AKLD CADILAHC CDLYY 532454 532872 532321 FORTIS SUNPHARMA 500477 BHARTIARTL AKLS CLNDY COALINDIA ASHOKLEY

 
Twist in tale: Religare Enterprises moves NCLT to recover siphoned funds from Singh Brothers

2018-09-14 moneycontrol
In a new and significant twist to the ongoing Singh brothers saga, Religare Enterprises has moved to the National Company Law Tribunal (NCLT) to recover funds siphoned off from the company held by the two siblings.
FORTIS OSCAR 532915 RELIGARE 501179 532843

 
NCLT allows Shivinder to withdraw plea against brother

2018-09-14 livemint
New Delhi: The NCLT on Friday allowed former Fortis Healthcare promoter Shivinder Mohan Singh to withdraw his petition against elder brother Malvinder Mohan Singh and ex-Religare chief Sunil Godhwani.
FORTIS 532915 RELIGARE 532843

 
Shivinder Singh says split with brother Malvinder stands, but intends to resolve differences through mediation

2018-09-14 moneycontrol
Shivinder Singh, who withdrew his petition from the National Company Law Tribunal (NCLT) against his elder brother Malvinder Singh citing respect for their mother, on Friday said he intends to use the “mediation process” to resolve differences amicably but his decision to disassociate from his brother stands.
FORTIS 532915 RELIGARE 532843

 
Fortis Healthcare up 1% after Shivinder Singh withdraws NCLT petition against Malvinder Singh

2018-09-14 moneycontrol
Shares of Fortis Healthcare added 1.5 percent intraday Friday after Shivinder Mohan Singh withdrew his petition against Malvinder Singh from the NCLT.
5225 FORTIS 532915 RELIGARE Q0F IHHHF 532843

 
Shivinder withdraws petition in NCLT against elder brother Malvinder

2018-09-13 livemint
New Delhi: Shivinder Singh, the younger of the two warring brothers whose business empire was once worth billions, requested a court on Thursday to withdraw a case he had filed against brother Malvinder after their mother and family elders brokered a truce between the siblings.
FORTIS 532915 RELIGARE 532843

 
Shivinder Mohan Singh withdraws NCLT petition against elder brother Malvinder Singh

2018-09-13 moneycontrol
The feud between brothers Shivinder Mohan Singh and Malvinder Singh took a new turn on Thursday when the former withdrew his petition from the NCLT citing respect for their mother.
FORTIS 532915 RELIGARE 532843

 
Shivinder Mohan Singh withdraws NCLT petition against elder brother Malvinder

2018-09-13 moneycontrol
The feud between brothers Shivinder Mohan Singh and Malvinder Singh took a new turn on Thursday when the former withdrew his petition from the NCLT citing respect for their mother.
FORTIS 532915 RELIGARE 532843

 
Singh brothers to fight Daiichi Sankyo separately as split widens

2018-09-12 livemint
New Delhi: Malvinder Singh and Shivinder Singh will be represented by separate counsels in the case filed by Japan’s Daiichi Sankyo Co. in a Delhi court to enforce the ₹ 3,500 crore arbitration award against the Singh brothers. Last week, Shivinder Singh disassociated himself from the business dealings of elder brother Malvinder.
FORTIS 532843

 
Pharma weekly wrap: A busy week with Aurobindo#39;s US buyout and break-up of Singh brothers

2018-09-08 moneycontrol
The biggest development of the week was India’s second-largest drugmaker Aurobindo Pharma's acquisition of commercial operations and three manufacturing units from Sandoz, a Novartis generic division, in the United States.
FORTIS AUROPHARMA 524804 ARBQY 532915 RELIGARE 532843

 
Fortis arm sells 15 lakh shares in RHT to FHIL

2018-09-07 thehindubusinessline
Fortis Healthcare on Friday said its step-down subsidiary, RHT Health Trust Manager, has sold 15 lakh shares in RHT Health Trust to Fortis Healthcare International Ltd (FHIL) for SGD 11,70,000. FHIL is a wholly-owned subsidiary of Fortis Healthcare Ltd (FHL).
FORTIS 532843

 
Fortis Healthcare Limited - Updates

2018-09-07 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
FORTIS 532843

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...